Compare Merck & Co., Inc. (MRK) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs PAGSEG Inc — how do they compare? Merck & Co., Inc. trades at $145.83 (market cap $351.28B), while PAGSEG Inc trades at $11.16 (market cap $2.94B). The key difference: Merck & Co., Inc. is far larger — about 119.5× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (10.49%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and PAGSEG Inc for 26 Days on average.
| MRK | PAGS | |
|---|---|---|
Market Cap | $351.28B | $2.94B |
Volume | 7,969,665 | 4,242,708 |
Sector | Health | Industrials |
52-Week High | $156.43 | $12.00 |
52-Week Low | $82.49 | $8.44 |
Typical Hold Time | 98 Days | 26 Days |
Enterprise Value | $398.04B | $11.02B |
Dividend Yield | 2.39% | 10.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
PAGS trades at $11.13, up 5.9% in the last 24 hours, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 7.1 and robust profitability, including a 10.45% net income margin. Recent earnings beat expectations in Q2 2026, and the company maintains a solid dividend yield, supported by positive cash flow from operations of $7.56B in 2025.
The outlook for PAGS is positive, driven by undervaluation and earnings growth potential, but risks include macroeconomic pressures in Brazil and increased credit losses. Analyst consensus is strongly bullish with a $10.70 price target, though near-term volatility may persist due to mixed technical oscillators and competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
